Royalty Pharma Reports First Quarter 2024 Results
NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts.
News
Royalty Pharma published press releases by date and/or category
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approximately $525 million in cash including estimated transaction costs.
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, NY, April 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open.
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, NY, April 17, 2024 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
NEW YORK, NY, February 28, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET.
Royalty Pharma Reports Q4 and Full Year 2023 Results
NEW YORK, NY, February 15, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2023 and introduced full year 2024 guidance for Portfolio Receipts.
Royalty Pharma to Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
NEW YORK, NY, January 30, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open.
Royalty Pharma Announces Dividend Increase
NEW YORK, NY, January 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, NY, January 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023 outlook for Portfolio Receipts.
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
NEW YORK, NY, November 27, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.
